Combination therapy for MDS
US9504706B2 · kind B2 · utility
5Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 1, 2015 |
| Grant date | Nov 29, 2016 |
| Priority date | — |
| Expiry date | Sep 1, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/531
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.